Maravai LifeSciences Holdings, Inc. $MRVI Position Raised by VELA Investment Management LLC

Key Points

• VELA Investment Management LLC increased its stake in Maravai LifeSciences by 55.4%, owning approximately 0.10% of the company after purchasing additional shares during the second quarter.
• Maravai LifeSciences received varied ratings from analysts, with the average rating being "Hold" and a consensus price target of $5.22.
• As of now, institutional investors hold 50.25% of Maravai LifeSciences' stock, indicating a significant interest from larger investment entities.

VELA Investment Management LLC raised its stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 55.4% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 242,962 shares of the company's stock after buying an additional 86,628 shares during the quarter. VELA Investment Management LLC owned approximately 0.10% of Maravai LifeSciences worth $586,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Philosophy Capital Management LLC bought a new stake in shares of Maravai LifeSciences during the first quarter valued at about $5,731,000. 12 West Capital Management LP raised its stake in shares of Maravai LifeSciences by 8.0% during the first quarter. 12 West Capital Management LP now owns 12,521,335 shares of the company's stock valued at $27,672,000 after purchasing an additional 930,000 shares in the last quarter. Deutsche Bank AG raised its stake in shares of Maravai LifeSciences by 67.6% during the first quarter. Deutsche Bank AG now owns 2,072,239 shares of the company's stock valued at $4,580,000 after purchasing an additional 835,600 shares in the last quarter. CenterBook Partners LP raised its stake in shares of Maravai LifeSciences by 67.2% during the first quarter. CenterBook Partners LP now owns 1,357,600 shares of the company's stock valued at $3,000,000 after purchasing an additional 545,674 shares in the last quarter. Finally, Monaco Asset Management SAM raised its stake in shares of Maravai LifeSciences by 186.9% during the first quarter. Monaco Asset Management SAM now owns 835,865 shares of the company's stock valued at $1,847,000 after purchasing an additional 544,501 shares in the last quarter. 50.25% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

MRVI has been the topic of a number of recent analyst reports. Royal Bank Of Canada cut their price objective on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 12th. Weiss Ratings restated a "sell (d-)" rating on shares of Maravai LifeSciences in a research note on Tuesday. Three equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $5.22.

Maravai LifeSciences Trading Up 3.6%

Shares of MRVI opened at $3.49 on Friday. The business's 50-day moving average price is $2.73 and its 200 day moving average price is $2.40. The stock has a market capitalization of $891.21 million, a P/E ratio of -2.57 and a beta of 0.33. Maravai LifeSciences Holdings, Inc. has a 1-year low of $1.66 and a 1-year high of $8.53. The company has a current ratio of 5.16, a quick ratio of 4.49 and a debt-to-equity ratio of 0.68.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

Want to see what other hedge funds are holding MRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.